Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice

Abstract

Background: Existing methods for preparing influenza vaccines pose the greatest challenge against highly pandemic avian influenza H7N9 outbreak in the poultry and humans. Exploring a new strategy for manufacturing and delivering a safe and effective H7N9 vaccine is needed urgently. Results: An alternative approach is to develop an influenza H7N9 oral vaccine based on yeast display technology in a timely manner. Hemagglutinin (HA) of A/Anhui/1/2013 (AH-H7N9) is used as a model antigen and characterized its expression on the surface of Saccharomyces cerevisiae (S.cerevisiae) EBY 100. Mice administrated orally with S.cerevisiae EBY100/pYD5-HA produced significant titers of IgG antibody as well as significant amounts of cytokines IFN-γ and IL-4. Importantly, S.cerevisiae EBY100/pYD5-HA could provide effective immune protection against homologous A/ Anhui/1/2013 (AH-H7N9) virus challenge. Conclusions: Our findings suggest that platform based on yeast surface technology provides an alternative approach to prepare a promising influenza H7N9 oral vaccine candidate that can significantly shorten the preparedness period and result in effective protection against influenza A pandemic.

Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in mice

“…Saccharomyces cerevisiae is an ideal eukaryotic host and has been engineered to express bacterial, viral or tumour antigens [ 24 ]. Oral vaccination of S. cerevisiae surface-displayed vaccine candidates has shown promise for preventing bacterial or viral infection [ 25 – 27 ]. In our previous studies, oral administration of H7N9 HA on the surface of S. cerevisiae provided 100% protective efficacy against homologous virus challenge in a mouse model [ 25 ].…”

“…Oral vaccination of S. cerevisiae surface-displayed vaccine candidates has shown promise for preventing bacterial or viral infection [ 25 – 27 ]. In our previous studies, oral administration of H7N9 HA on the surface of S. cerevisiae provided 100% protective efficacy against homologous virus challenge in a mouse model [ 25 ]. Furthermore, the immunogenicity of UreB or VacA of Helicobacter pylori ( H. pylori ) expressed on the S. cerevisiae surface was also investigated [ 26 ].…”

High immune efficacy against different avian influenza H5N1 viruses by oral administration of a Saccharomyces cerevisiae-based vaccine in chickens

“…Conventional injection administration of EBY100/pYD1-HA in mice provided effective immune protection against A (H5N1) virus challenge [15]. Furthermore, we generated another yeast-based H7N9 oral vaccine could also protect mice from A (H7N9) challenge [20]. In the present study, we extend our previous work by investigating the immunogenicity of EBY100/pYD1-HA with oral administration and evaluating the cross-protective immunity of EBY100/pYD1-HA in chicken model.…”

“…Quanti cation of HA protein was determined by indirect enzyme-link immunosorbent assay (ELISA) as described previously [20]. In a brief, 5 OD 600nm of EBY100/pYD1-HA pellets were re-suspended in 100 µL…”

High immune efficacy against different avian influenza H5N1 viruses due to oral administration of a Saccharomyces cerevisiae-based vaccine in chickens

“…We have previously shown that EBY100/pYD1-HA could provide protection when administered by injection route in a mouse model 15 . However, EBY100/pYD1-HA induces serious inflammation at the injection site due to the diameter of S. cerevisiae is approximately 10 μm 19 , 20 . Furthermore, chickens are the primary model for studies of pathogenicity and vaccine efficacy studies for poultry 21 .…”